FibroGen Future Growth
Future criteria checks 1/6
FibroGen is forecast to grow earnings and revenue by 44.9% and 10.4% per annum respectively while EPS is expected to grow by 47.1% per annum.
Key information
44.9%
Earnings growth rate
47.1%
EPS growth rate
Biotechs earnings growth | 23.7% |
Revenue growth rate | 10.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 18 Apr 2024 |
Recent future growth updates
Recent updates
FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Mar 22There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise
Feb 05FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%
Dec 22A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)
Nov 24Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)
Apr 18Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Feb 13The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts
Nov 12Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Oct 09FibroGen completes patient enrollment for Roxadustat to treat anemia in patients
Aug 26FibroGen Q2 2022 Earnings Preview
Aug 05Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Jul 06Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Mar 31Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook
Mar 05Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?
Dec 08News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are Under Threat
Aug 12Downgrade: Here's How Analysts See FibroGen, Inc. (NASDAQ:FGEN) Performing In The Near Term
Jul 17Is FibroGen A Buy Going Into Roxa AdCom?
Jul 13FibroGen in pact for three HiFiBiO programs in cancer and autoimmune disease
Jun 17Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 205 | -88 | N/A | N/A | 2 |
12/31/2025 | 169 | -102 | N/A | N/A | 3 |
12/31/2024 | 155 | -142 | N/A | N/A | 3 |
12/31/2023 | 148 | -284 | -318 | -315 | N/A |
9/30/2023 | 155 | -294 | -352 | -349 | N/A |
6/30/2023 | 131 | -322 | -319 | -317 | N/A |
3/31/2023 | 116 | -307 | -242 | -239 | N/A |
12/31/2022 | 141 | -294 | -185 | -146 | N/A |
9/30/2022 | 123 | -362 | -188 | -148 | N/A |
6/30/2022 | 263 | -220 | -118 | -52 | N/A |
3/31/2022 | 258 | -281 | -112 | -46 | N/A |
12/31/2021 | 235 | -290 | -112 | -82 | N/A |
9/30/2021 | 284 | -215 | -66 | -34 | N/A |
6/30/2021 | 172 | -231 | -85 | -80 | N/A |
3/31/2021 | 190 | -183 | 92 | 96 | N/A |
12/31/2020 | 176 | -189 | 78 | 82 | N/A |
9/30/2020 | 119 | -229 | 40 | 44 | N/A |
6/30/2020 | 108 | -311 | 13 | 18 | N/A |
3/31/2020 | 257 | -110 | -166 | -161 | N/A |
12/31/2019 | 257 | -77 | -84 | -79 | N/A |
9/30/2019 | 357 | 42 | -58 | -51 | N/A |
6/30/2019 | 353 | 49 | -22 | -15 | N/A |
3/31/2019 | 205 | -90 | -28 | -22 | N/A |
12/31/2018 | 213 | -86 | -84 | -76 | N/A |
9/30/2018 | 136 | -141 | -68 | -60 | N/A |
6/30/2018 | 147 | -123 | -97 | -87 | N/A |
3/31/2018 | 133 | -132 | -81 | -71 | N/A |
12/31/2017 | 131 | -121 | -75 | -67 | N/A |
9/30/2017 | 132 | -121 | N/A | -84 | N/A |
6/30/2017 | 122 | -121 | N/A | -67 | N/A |
3/31/2017 | 181 | -64 | N/A | -3 | N/A |
12/31/2016 | 183 | -58 | N/A | 7 | N/A |
9/30/2016 | 172 | -79 | N/A | -14 | N/A |
6/30/2016 | 162 | -100 | N/A | -50 | N/A |
3/31/2016 | 193 | -67 | N/A | 6 | N/A |
12/31/2015 | 181 | -86 | N/A | -19 | N/A |
9/30/2015 | 172 | -85 | N/A | -3 | N/A |
6/30/2015 | 167 | -79 | N/A | 4 | N/A |
3/31/2015 | 136 | -98 | N/A | -4 | N/A |
12/31/2014 | 138 | -60 | N/A | 22 | N/A |
9/30/2014 | 134 | -24 | N/A | 24 | N/A |
6/30/2014 | 191 | 43 | N/A | 128 | N/A |
3/31/2014 | 117 | -5 | N/A | 30 | N/A |
12/31/2013 | 102 | -15 | N/A | 26 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FGEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FGEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FGEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FGEN's revenue (10.4% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: FGEN's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FGEN's Return on Equity is forecast to be high in 3 years time